SCHEMBL715804

SCHEMBL715804

COc1cc(OC)c(OC)cc1/C=C/C(=O)O

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFE2L2 Q16236 1/20 0.76
ABCG2 Q9UNQ0 1/20 0.67
KDM4E B2RXH2 7/20 0.59
ALDH1A1 P00352 5/20 0.59
SMN1; SMN2 Q16637 3/20 0.59
HPGD P15428 2/20 0.59
HSD17B10 Q99714 2/20 0.59
ALOX15 P16050 1/20 0.59
MAPK1 P28482 1/20 0.59
HMGCR P04035 1/20 0.57
CYP3A4 P08684 1/20 0.57
PKM P14618 2/20 0.56
HTR1A P08908 1/20 0.56
HTR2C P28335 1/20 0.56
PTGS1 P23219 1/20 0.56
PTGS2 P35354 1/20 0.56
SNCA P37840 3/20 0.56
GAA P10253 2/20 0.55
APP P05067 1/20 0.54
TSHR P16473 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL715805 1.00 NFE2L2 (0.76) NFE2L2ABCG2KDM4EALDH1A1SMN1; SMN2
SCHEMBL30871940 1.00 NFE2L2 (0.76) NFE2L2ABCG2KDM4EALDH1A1SMN1; SMN2
SCHEMBL6852559 0.96 NFE2L2 (0.69) NFE2L2ABCG2KDM4EALDH1A1SMN1; SMN2
SCHEMBL6852555 0.96 NFE2L2 (0.69) NFE2L2ABCG2KDM4EALDH1A1SMN1; SMN2
SCHEMBL8572433 0.87 NFE2L2 (0.59) NFE2L2ABCG2KDM4EALDH1A1SMN1; SMN2
SCHEMBL7138837 0.87 NFE2L2 (0.59) NFE2L2ABCG2KDM4EALDH1A1SMN1; SMN2
SCHEMBL28662544 0.87 KDM4E (0.59) NFE2L2ABCG2KDM4EALDH1A1SMN1; SMN2
SCHEMBL28662543 0.87 KDM4E (0.59) NFE2L2ABCG2KDM4EALDH1A1SMN1; SMN2
SCHEMBL2744488 0.86 NFE2L2 (1.00) NFE2L2ABCG2KDM4EALDH1A1MAPK1
SCHEMBL2744657 0.86 NFE2L2 (1.00) NFE2L2ABCG2KDM4EALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7732625-B2 Colorant compounds XEROX CORPORATION (US) 2010-06-08 US claimed
US-7311767-B2 Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens XEROX CORPORATION (US) 2007-12-25 US claimed
US-7033424-B2 Phase change inks XEROX CORPORATION (US) 2006-04-25 US claimed
US-20060021546-A1 Processes for preparing phase change inks XEROX CORPORATION 2006-02-02 US claimed
US-20060020141-A1 Metallized dye XEROX CORPORATION 2006-01-26 US claimed
US-20060016369-A1 PHASE CHANGE INKS XEROX CORPORATION 2006-01-26 US claimed
US-6946025-B2 Process for preparing tetra-amide compounds XEROX CORPORATION (US) 2005-09-20 US claimed
US-6916890-B1 Thermally reworkable epoxy resins and compositions based thereon HENKEL CORPORATION (US) 2005-07-12 US claimed
US-20050090690-A1 Process for preparing tetra-amide compounds XEROX CORPORATION 2005-04-28 US claimed
WO-2003031492-A1 THERMALLY REWORKABLE EPOXY RESINS AND COMPOSITIONS BASED THEREO N HENKEL CORPORATION (US) 2003-04-17 WO claimed
US-5866608-A AROMATIC COMPOUNDS BIORESEARCH, INC. (US) 1999-02-02 US claimed
CN-117990868-A Method for evaluating influence of yoghurt on flavone and phenolic acid in orange juice by adopting in-vitro model simulating gastrointestinal digestion 上海交通大学医学院 2024-05-07 CN disclosed
CN-117794534-A Compositions for modulating cortisol homeostasis and improving sleep quality and methods of use and preparation thereof 尤尼根公司 2024-03-29 CN disclosed
CN-113387804-B Synthesis method of alpha-asarone acetate and alpha-octanol 西安石油大学 2023-05-02 CN disclosed
CN-113248380-B Synthetic method of acetic acid alpha-asaryl alcohol ester and alpha-fine octanol 西北大学 2023-01-10 CN disclosed
US-4247597-A Electroscopic carrier particles having a carboxylic acid surface treatment PITNEY BOWES, INC. (US) 1981-01-27 US disclosed
US-4070484-A Antiallergic composition containing aromatic carboxylic amide derivatives and method of using the same KISSEI PHARMACEUTICAL CO., LTD. (JA) 1978-01-24 US disclosed
US-3995054-A MITICIDES ZOECON CORPORATION (US) 1976-11-30 US disclosed
US-3975429-A Cyclopropanemethyl esters of cinnamic acid and derivatives thereof ZOECON CORPORATION (US) 1976-08-17 US disclosed
US-3940422-A ANTIALLERGEN KISSEI YAKUHIN KOGYO KABUSHIKI KAISHA (JA) 1976-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060020141-A1 Metallized dye CDYL, CDY1; CDY1B, CDYL2 NFE2L2 1266/4885ABCG2 1946/4885KDM4E 1814/4885
US-20050090690-A1 Process for preparing tetra-amide compounds TAF9, TAF5, TAF1 NFE2L2 3435/4885ABCG2 3845/4885KDM4E 1567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.